Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Allergan depression treatment fails studies, shares slip

Allergan Plc’s experimental add-on treatment for depression failed three late-stage studies, casting doubts over the company’s drug pipeline and sending the Botox maker’s shares down nearly 4 percent.

Read More »

London HIV patient becomes world’s second AIDS cure hope

An HIV-positive man in Britain became the second known adult worldwide to be cleared of the AIDS virus after he received a bone marrow transplant from an HIV resistant donor, his doctors said.

Read More »

Novo Nordisk’s Ozempic Continues to Show Superiority in Diabetes Control

Novo Nordisk announced the results from a Phase IIIb trial comparing Ozempic (semaglutide) with an SGLT-2 inhibitor or placebo in adults with type 2 diabetes.

Read More »

ImmunoGen drug fails cancer study

ImmunoGen Inc.’s experimental ovarian cancer drug failed to meet the main goal of a late-stage study, driving the U.S. drug developer’s shares more than 40 percent lower.

Read More »

Novavax respiratory vaccine fails in late-stage trial

Novavax Inc.’s vaccine to prevent RSV infection, a leading cause of a respiratory disease in infants, failed to meet the main goal of a late-stage study.

Read More »

Bacteriophages to the Rescue: A Possible Approach to Antibiotic Resistance

A bacteriophage is a virus that infects bacteria. They are not typically used to treat bacterial infections, but in desperate cases, they have been used to treat particularly antibiotic-resistant infections.

Read More »

Parkinson’s drug trial offers glimmer of hope for brain cells

An experimental drug could offer hope for restoring damaged brain cells in Parkinson’s patients, scientists said on Wednesday, although they cautioned that a clinical trial was not able to prove the treatment slowed or halted the neurodegenerative disease.

Read More »

Lynparza meets main goal in pancreatic cancer study

AstraZeneca Plc said the British drugmaker’s cancer drug being jointly developed with U.S.-based Merck & Co. met the primary goal in a late-stage study for a rare type of pancreatic cancer.

Read More »

Japan scientists win backing for work on potential Nipah vaccine

A global coalition set up to fight emerging epidemics struck a $31 million deal with scientists at Japan’s University of Tokyo to speed up work on a vaccine against a brain-damaging disease caused by the Nipah virus.

Read More »

Opiant’s Mid-Stage Treatment for a Severe Eating Disorder Fails to Reach Endpoints

Shares of Opiant Pharmaceuticals fell in trading after the company announced that the Phase II trial evaluating a naloxone nasal spray for the treatment of bulimia nervosa failed to meet primary endpoints and will discontinue the program.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom